doi: 10.1136/annrheumdis-2013-204105 88 CuriRNewsholmePMarzuca-NassrGNTakahashiHKHirabaraSMCruzatVet al
Wegovy is a GLP-1 receptor agonist that mainly affects blood sugar control, appetite, and digestion, not reproductive hormones
The appetite-regulating and impulse-modulating properties of these medications offer real clinical benefit for a population with historically limited pharmacological options
Zhang, J., et al., Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management
3 Neuroscience Research Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
These include: Nausea Vomiting Diarrhoea Constipation Decreased appetite (which, whilst therapeutically intended, can occasionally be excessive) Injection-site reactions (such as redness, bruising, or discomfort at the injection site) These effects were generally mild to moderate in severity and most frequently occurred during the dose-escalation phase of treatment, tending to diminish over time